Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVA237 vs Tiotropium in COPD (GLOW2)
NCT01513460Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2012
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of glycopyrronium in chronic obstructive pulmonary disease (COPD), sponsored by Novartis. Started Apr 2012; status: completed.
02
Drugs
glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01513460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01513460.